via Massachusetts General Hospital
Key Takeaways
- Parathyroid hormone–based medications can stimulate bone formation to treat osteoporosis but are only effective when administered by injection
- Researchers have now identified an oral compound that influences components of the parathyroid hormone signaling pathway to increase bone formation and bone mass in mice
- The investigators are currently working to optimize and develop this compound into a new therapy for patients
Parathyroid hormone can stimulate bone formation, and analogs of the hormone are often prescribed to patients with osteoporosis; however, these medications are only effective when administered by daily injection.
A team led by investigators at Massachusetts General Hospital (MGH) recently identified a promising compound that influences components of the parathyroid hormone signaling pathway and that, when given orally to mice, increases bone mass. The group’s discovery, which is published in PNAS, might lead to a new, more convenient drug for preventing and treating osteoporosis.
“Currently there are no orally available medications for osteoporosis that stimulate bone formation. We sought to develop such medications based upon our detailed understanding of the pathways that normally govern bone production,” says senior author Marc Wein, MD, PhD, an endocrinologist at MGH and an Assistant Professor of Medicine at Harvard Medical School.
The pathway that involves parathyroid hormone inhibits salt-inducible kinase isoforms 2 and 3 (SIK2 and SIK3), which are enzymes with roles in the regulation of bone growth and remodeling.
Wein and his colleagues generated a novel structural model of these enzymes and then used advanced methods including structure-based drug design and iterative medicinal chemistry to identify a compound that potently inhibits SIK2 and SIK3. This compound, termed SK-124, had parathyroid hormone–like effects when given to cells and, most importantly, when fed to mice. In mice, oral treatment once a day for three weeks increased blood levels of calcium and vitamin D and also boosted bone formation and bone mass without evidence of short-term toxicity.
“Based on these findings, we propose that small molecules like SK-124 might represent ‘next generation’ oral bone building therapies for osteoporosis,” says Wein. “We are currently collaborating with a pharmaceutical company—Radius Health, Inc.—to further optimize and develop this compound into a treatment for patients.”
Original Article: New Oral Compound Developed by Mass General Researchers May Help Prevent and Treat Osteoporosis
More from: Massachusetts General Hospital
The Latest Updates from Bing News
Go deeper with Bing News on:
Osteoporosis treatment
- People with acute calcium pyrophosphate face doubled risk for fracture
Fracture risk is nearly doubled in individuals with acute calcium pyrophosphate (CPP) crystal arthritis, according to a study recently published in Arthritis & Rheumatology.
- Selection of Antiresorptive or Anabolic Treatments for Postmenopausal Osteoporosis
the efficacy data do not clearly show that PTH should be selected over antiresorptive therapies for the treatment of osteoporosis. In addition, PTH is expensive and must be administered daily via ...
- Osteoarthritis, Osteoporosis and Osteopenia: What’s the Difference?
What's in a name? Well, if it's osteoporosis, osteopenia and osteoarthritis, for starters, a shared prefix. "Osteo" means bone, and that matching descriptor also spells confusion for many ...
- Alert over Facebook conspiracy theorists scaring women into quitting lifesaving osteoporosis drugs - as experts warn patients are risking death if they stop taking treatment
Women are quitting vital drugs that treat the bone-thinning disease osteoporosis because of 'dangerous misinformation' about their side effects being spread on Facebook, experts have warned.
- Zoledronic acid for osteoporosis treatment—a matter of time
in comparison to ... weekly oral alendronate Adherence to treatment is a considerable concern in all areas of medicine. With respect to patients with osteoporosis, an annual intravenous infusion ...
Go deeper with Bing News on:
Osteoporosis
- Sandoz reaches agreement with Amgen resolving all patent litigation related to its US denosumab biosimilars
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesSandoz reaches agreement with Amgen resolving all patent litigation ...
- I’m a longevity expert — I swear by these 5 supplements for aging
Getting older can be a tough pill to swallow, but according to a longevity expert, the right supplements can ease the process.
- Osteoarthritis, Osteoporosis and Osteopenia: What’s the Difference?
What's in a name? Well, if it's osteoporosis, osteopenia and osteoarthritis, for starters, a shared prefix. "Osteo" means bone, and that matching descriptor also spells confusion for many ...
- Osteoporosis services in a ‘chronic state’
When over-fifties fracture bones from minor falls, scanning could show if they have this debilitating condition, and steps can be taken to treat it. Major delays and lack of scanners means this isn’t ...
- Treatment of osteoporosis with Denosumab associated with lower risk of incident diabetes especially among elderly: JAMA
Denosumab treatment is associated with a lower risk of incident diabetes especially among elderly patients with osteoporosis, suggests a new study published in the JAMA Network Open.Denosumab, ...
